GlassScriptPhysician profile
Nisarg S Shah
NPI 1124469531
$8,992.21
in general payments reported to CMS, 2019-2025
41 companies · $2,748 in 2025
The $2,748 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $378 · 2021: $346 · 2022: $987 · 2023: $1,151 · 2024: $2,614 · 2025: $2,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,012 · Honoraria: $325 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,012.36 |
| Honoraria | $325.00 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $891.92 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $887.72 | 2019-2025 | Ozempic, Sogroya, Rybelsus |
| Amgen INC. | $639.14 | 2019-2025 | Tepezza, Prolia, Evenity |
| Corcept Therapeutics | $596.95 | 2019-2025 | Korlym |
| Dexcom, INC. | $506.74 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Kyowa Kirin, INC. | $462.63 | 2024-2025 | Crysvita |
| Abbott Laboratories | $438.41 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $390.18 | 2019-2024 | |
| Insulet Corporation | $373.10 | 2024-2025 | Omnipod |
| Chiesi USA, INC. | $325.00 | 2025 | Myalept |
| Beta Bionics, INC. | $299.38 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $273.26 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $254.30 | 2022-2025 | |
| Mannkind Corporation | $234.73 | 2022-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.31 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $198.64 | 2024 | Veozah |
| Medtronic, INC. | $181.35 | 2022-2024 | Inpen Smart Insulin Delivery System |
| Madrigal Pharmaceuticals | $171.51 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $151.52 | 2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $148.20 | 2019-2023 | Farxiga |
| Neurocrine Biosciences, INC. | $143.68 | 2024-2025 | |
| Genzyme Corporation | $142.00 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $130.91 | 2024 | Rayaldee |
| Shire North American Group INC | $120.25 | 2019 | |
| Xeris Pharmaceuticals, INC. | $115.64 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Boston Scientific Corporation | $111.76 | 2024 | |
| Alexion Pharmaceuticals, INC. | $100.84 | 2024 | Strensiq |
| Cequr Corporation | $95.36 | 2024 | Cequr Simplicity |
| Chiasma, INC. | $73.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $56.63 | 2024-2025 | |
| Pfizer INC. | $55.00 | 2022 | |
| Abbvie INC. | $40.72 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $21.55 | 2025 | Nuzyra |
| Recordati_rare_diseases_inc. | $20.25 | 2024 | Signifor Lar, Isturisa |
| Amryt Pharma Holdings LTD | $19.84 | 2023 | Mycapssa |
| Antares Pharma, INC. | $18.07 | 2023 | Tlando, Xyosted, Nocdurna |
| Halozyme INC | $16.91 | 2023 | |
| Sequel Med Tech, LLC | $15.49 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $15.34 | 2025 | Imcivree |
| Companion Medical, INC. | $14.64 | 2019 | |
| Currax Pharmaceuticals LLC | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisarg Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.